An open-label study adding creatine monohydrate to ongoing medical regimens in patients with the fibromyalgia syndrome

Avi Leader; Daniella Amital; Alan Rubinow; Howard Amital

doi:10.1111/j.1749-6632.2009.04811.x

An open-label study adding creatine monohydrate to ongoing medical regimens in patients with the fibromyalgia syndrome

Avi Leader, Daniella Amital, Alan Rubinow, Howard Amital^*

^*Corresponding author for this work

Clinical Departments

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

Abstract

Fibromyalgia is an ill-defined condition that causes pain and disability but still lacks effective treatment. The aim of this open-label study was to assess the efficacy of administering a food supplement, creatine monohydrate, in an "add on" to existing therapies in patients with fibromyalgia. This study included 30 patients with fibromyalgia. After 8 weeks of receiving creatine, we witnessed a significant improvement in parameters reflecting severity of fibromyalgia, quality of life and sleep, disability, and pain. These results deteriorated 4 weeks after stopping creatine therapy. The findings of this study are preliminary and limited due to the small sample and relatively high rate of dropouts.

Original language	English
Title of host publication	Contemporary Challenges in Autoimmunity
Publisher	Blackwell Publishing Inc.
Pages	829-836
Number of pages	8
ISBN (Print)	9781573317627
DOIs	https://doi.org/10.1111/j.1749-6632.2009.04811.x
State	Published - Sep 2009

Publication series

Name	Annals of the New York Academy of Sciences
Volume	1173
ISSN (Print)	0077-8923
ISSN (Electronic)	1749-6632

Keywords

Anxiety
Depression
Fibromyalgia
Pain
Quality of life

Access to Document

10.1111/j.1749-6632.2009.04811.x

Cite this

@inproceedings{ca871d90282c49428705d6558c1ac478,

title = "An open-label study adding creatine monohydrate to ongoing medical regimens in patients with the fibromyalgia syndrome",

abstract = "Fibromyalgia is an ill-defined condition that causes pain and disability but still lacks effective treatment. The aim of this open-label study was to assess the efficacy of administering a food supplement, creatine monohydrate, in an {"}add on{"} to existing therapies in patients with fibromyalgia. This study included 30 patients with fibromyalgia. After 8 weeks of receiving creatine, we witnessed a significant improvement in parameters reflecting severity of fibromyalgia, quality of life and sleep, disability, and pain. These results deteriorated 4 weeks after stopping creatine therapy. The findings of this study are preliminary and limited due to the small sample and relatively high rate of dropouts.",

keywords = "Anxiety, Depression, Fibromyalgia, Pain, Quality of life",

author = "Avi Leader and Daniella Amital and Alan Rubinow and Howard Amital",

year = "2009",

month = sep,

doi = "10.1111/j.1749-6632.2009.04811.x",

language = "אנגלית",

isbn = "9781573317627",

series = "Annals of the New York Academy of Sciences",

publisher = "Blackwell Publishing Inc.",

pages = "829--836",

booktitle = "Contemporary Challenges in Autoimmunity",

}

An open-label study adding creatine monohydrate to ongoing medical regimens in patients with the fibromyalgia syndrome. / Leader, Avi; Amital, Daniella; Rubinow, Alan et al.
Contemporary Challenges in Autoimmunity. Blackwell Publishing Inc., 2009. p. 829-836 (Annals of the New York Academy of Sciences; Vol. 1173).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - An open-label study adding creatine monohydrate to ongoing medical regimens in patients with the fibromyalgia syndrome

AU - Leader, Avi

AU - Amital, Daniella

AU - Rubinow, Alan

AU - Amital, Howard

PY - 2009/9

Y1 - 2009/9

N2 - Fibromyalgia is an ill-defined condition that causes pain and disability but still lacks effective treatment. The aim of this open-label study was to assess the efficacy of administering a food supplement, creatine monohydrate, in an "add on" to existing therapies in patients with fibromyalgia. This study included 30 patients with fibromyalgia. After 8 weeks of receiving creatine, we witnessed a significant improvement in parameters reflecting severity of fibromyalgia, quality of life and sleep, disability, and pain. These results deteriorated 4 weeks after stopping creatine therapy. The findings of this study are preliminary and limited due to the small sample and relatively high rate of dropouts.

AB - Fibromyalgia is an ill-defined condition that causes pain and disability but still lacks effective treatment. The aim of this open-label study was to assess the efficacy of administering a food supplement, creatine monohydrate, in an "add on" to existing therapies in patients with fibromyalgia. This study included 30 patients with fibromyalgia. After 8 weeks of receiving creatine, we witnessed a significant improvement in parameters reflecting severity of fibromyalgia, quality of life and sleep, disability, and pain. These results deteriorated 4 weeks after stopping creatine therapy. The findings of this study are preliminary and limited due to the small sample and relatively high rate of dropouts.

KW - Anxiety

KW - Depression

KW - Fibromyalgia

KW - Pain

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=69949185907&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2009.04811.x

DO - 10.1111/j.1749-6632.2009.04811.x

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.conference???

C2 - 19758235

AN - SCOPUS:69949185907

SN - 9781573317627

T3 - Annals of the New York Academy of Sciences

SP - 829

EP - 836

BT - Contemporary Challenges in Autoimmunity

PB - Blackwell Publishing Inc.

ER -

An open-label study adding creatine monohydrate to ongoing medical regimens in patients with the fibromyalgia syndrome

Abstract

Publication series

Keywords

Access to Document

Other files and links

Fingerprint

Cite this